SARS-CoV-2 variants from mink evade inhibition by antibodies

It has been known for about a year that minks can become infected with SARS-CoV-2. The virus had been transmitted from humans to farmed mink and mutated in infected animals. Mutations were acquired in the spike protein, which is crucial for the entry of the virus into host cells and represents the central point of attack for antibodies. These SARS-CoV-2 variants from mink were transmitted back to humans, raising concerns that minks could be a continuing source of infection of humans with SARS-CoV-2 variants with altered biological properties. Researchers at the German Primate Center (DPZ) - Leibniz Institute for Primate Research in Göttingen, Germany, have now shown that an antibody used for COVID-19 therapy is unable to effectively inhibit SARS-CoV-2 harboring a spike mutation acquired in minks. In addition, the mutation reduced the inhibition of the virus by antibodies produced in SARS-CoV-2 infected humans. These results show that SARS-CoV-2 can acquire mutations in minks that may reduce control of the virus by the human immune system. The study and findings have been published in Cell Reports.

Deutsches Primatenzentrum: SARS-CoV-2 variants from mink evade inhibition by antibodies

Mutations arising in SARS-CoV-2 spike on sustained human-to-human transmission and human-to-animal passage - SARS-CoV-2 coronavirus - Virological

Neutralizing Antibodies to SARS‐CoV‐2 Selected from a Human Antibody Library Constructed Decades Ago - Qiang - 2022 - Advanced Science - Wiley Online Library

Frontiers The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2

Deutsches Primatenzentrum: SARS-CoV-2 variants from mink evade inhibition by antibodies

SARS-CoV-2 Variant Inhibitor Screening Kit (VANC00B)

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity - ScienceDirect

SARS-CoV-2 evolution in animals suggests mechanisms for rapid variant selection

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination - ScienceDirect

Frontiers SARS-COV-2 Variants: Differences and Potential of Immune Evasion

SARS-CoV-2 variants, spike mutations and immune escape

Microorganisms, Free Full-Text

Frontiers A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations